In conclusion, we demonstrate that the AK inhibitor alisertib synergizes with anti-PD-L1 treatment thus providing a novel backbone therapy for PTCL. This evidence concerns the gene CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma.